Prescription of pharmacotherapy and blood pressure control among hypertensive outpatients in two semi-urban hospitals in Cameroon: a cross-sectional study

Anastase Dzudie, Messaline Fodom Fomo, Denis Georges Teuwafeu, Clovis Nkoke, Azabji Kenfack, Divine Tim Bonghaseh, Domin Ekaney, Amy Tantchou, Cabral Tantchou, Laurent Serges Etoundi Ngoa, Andre Pascal Kangne, Simeon Pierre Choukem

Corresponding author: Anastase Dzudie, Department of Internal Medicine and Subspecialties, Douala General Hospital, Douala, Cameroon. aitdzudie@yahoo.com

Received: 18 Dec 2019 - Accepted: 02 Feb 2020 - Published: 05 Oct 2020

Keywords: Hypertension, antihypertensive drugs, blood pressure, Cameroon

Copyright: Anastase Dzudie et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Anastase Dzudie et al. Prescription of pharmacotherapy and blood pressure control among hypertensive outpatients in two semi-urban hospitals in Cameroon: a cross-sectional study. Pan African Medical Journal. 2020;37(122). 10.11604/pamj.2020.37.122.21156

Available online at: https://www.panafrican-med-journal.com/content/article/37/122/full

Prescription of pharmacotherapy and blood pressure control among hypertensive outpatients in two semi-urban hospitals in Cameroon: a cross-sectional study

Anastase Dzudie1,2,3,8, Messaline Fodom Fomo2, Denis Georges Teuwafeu4, Clovis Nkoke2,4, Azabji Kenfack4, Divine Tim Bonghaseh2,5,6, Domin Ekaney2,7, Amy Tantchou8, Cabral Tantchou9, Laurent Serges Etoundi Ngoa1, Andre Pascal Kangne2,10, Simeon Pierre Choukem3,5,11

1Department of Physiology, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon, 2Clinical Research Education Networking and Consultancy (CRENC), Douala, Cameroon, 3Department of Internal Medicine and Subspecialties, Douala General Hospital, Douala, Cameroon, 4Department of Internal Medicine,
Anastase Dzudie et al. PAMJ - 37(122). 05 Oct 2020. - Page numbers not for citation purposes.

Buea Regional Hospital, Buea, Cameroon, ¹Health and Human Development (2HD) Research Network, Douala, Cameroon, ²Baptist Hospital Mutengene, Mutengene, Cameroon, ³Subdivisional Hospital Batoke, Limbe, Cameroon, ⁴Mariner Finance, Maryland, USA, ⁵Shisong Cardiac Center, Kumbo, North West Region, Cameroon, ⁶Non-communicable Disease Research Unit, South African Medical Research Council, Cape Town, South Africa, ⁷Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon

Corresponding author
Anastase Dzudie, Department of Internal Medicine and Subspecialties, Douala General Hospital, Douala, Cameroon

Abstract

Introduction: several international guidelines are available on drug treatment for hypertension, but the control of hypertension remains very poor in sub-Saharan Africa (SSA). We investigated the commonly prescribed antihypertensive drugs and their association with blood pressure (BP) control in adult Cameroonians. Methods: we consecutively recruited hypertensive outpatients attending the Buea and Limbe Regional Hospitals (southwest region of Cameroon). Controlled BP was defined as BP < 140/90mmHg in hypertensive patients aged 60 years or younger, diabetics or patients with chronic kidney disease or a BP < 150/90mmHg in non-diabetic hypertensive patients older than 60 years of age (JNC8). Results: of the 408 participants included (mean age 61.1 years), 67% were female. The median duration of hypertension was 6 years and the median duration of the current treatment was 22 weeks. Commonly prescribed antihypertensives were calcium channel blockers (CCB, 35.1%), thiazide/thiazide-like diuretics (TD/TLD, 26.1%) and angiotensin-converting enzyme inhibitors (ACEI, 19.5%). The median monthly cost of antihypertensive was 10279.6 CFA (approximately equal to US$ 172). Seventy percent (70%) of participants were receiving at least 2 drugs, with ACEI+TD/TLD, CCB+TD/TLD, and ACEI+CCB+TD/TLD being the most frequent combination. The rate of BP control was 52% overall, and 60% in participants on monotherapy. Conclusion: CCBs were the most prescribed single antihypertensive drugs in this setting while ACEI+TD/TLD was the most common combination. About half of patients were at target BP control levels improving availability and affordability of these medications may improve hypertension management and control.

Introduction

Hypertension is a major global public health problem [1] and the leading contributor to cardiovascular diseases and deaths worldwide [2, 3]. In 2010, the estimated global population with hypertension was 1.39 billion people, representing 31% of all adults [4]. It is projected that this population will increase by about 60% to a total of 1.56 billion by 2025 [5]. According to the World Health Organisation (WHO), sub-Saharan Africa (SSA) has the highest and fast-growing prevalence of hypertension [6, 7]. Over a ten year period (between 1994 and 2003), the prevalence of hypertension increased by two to five folds amongst the urban and rural populations in Cameroon and in 2015, the prevalence of hypertension was reported at 29.7% [8]. The primary goal of antihypertensive drugs prescription is to prevent the complication of elevated blood pressure (BP) and studies have shown that antihypertensive treatment can achieve 35-40% reduction in stroke, 20-25% reduction in myocardial infarction (MI) and more than 50% reduction of heart failure [9]. However, more than two-thirds of hypertensive people cannot be controlled by one drug and will require two or more drugs selected from different classes to achieve and maintain the desired BP [10, 11].

Worldwide, treatment strategies have changed and gradually moved from monotherapy to low dose combination therapy [1]. Recent guidelines recommend both CCB and ACEI or angiotensin receptor blockers (ARB) in addition to diuretics as
the first-line drugs in the management of hypertension [12, 13]. Despite the existence of several guidelines for the management of hypertension [14-18], more than half of hypertensive patients do not achieve optimum BP [19, 20]. Despite this rising burden, there is no consensus on the management of hypertensive disorders across SSA countries. Treatment choices are usually adapted from guidelines from high-income countries. Thus, the prescription of antihypertensive drugs and their effectiveness vary across settings. Assessing current treatment strategies is an important step towards improving hypertension control. This study sought to determine the commonly prescribed antihypertensive drugs either in single or combination therapy and evaluate the effects on BP control in a semi-urban setting in Cameroon.

Methods

Study design, setting, and sampling: we conducted a hospital-based cross-sectional study, with data collected over a period of four months (January-April 2018) at two secondary referral hospitals of the Southwest Region (SWR) of Cameroon (Buea and Limbe Regional Hospitals). The Buea Regional Hospital (BRH) has a catchment population of over 200,000 inhabitants [21], Limbe Regional Hospital (LRH) has a catchment population of over 118,210 inhabitants as of 2015 [22]. The minimum sample size (321 participants) was calculated using the formula for the prevalence study by Cochran’s [23]. We consecutively recruited all consenting hypertensive patients aged 21 years and above with a documented diagnosis of hypertension and on antihypertensive drugs for at least 15 days consulting as outpatients in these two hospitals. Participants who were pregnant or didn’t consent were excluded.

Data collection: an adapted questionnaire from the WHO STEPs instrument for non-communicable diseases (NCDs) risk factors assessment was used [24]. Information on socio-demographic status (age, gender, marital status, level of education and occupation), participants’ clinical history (history of dyslipidemia, diabetes, stroke, heart failure, chronic kidney disease (CKD) and ischemic heart disease (IHD), smoking, alcohol and physical activity) and physical measurements (weight, height, and BP using WHO standard operating procedures) were obtained. Information about the duration of hypertension, duration of current treatment, BP at the start of current treatment, lists of BP-lowering medications were obtained from participants’ medical records. Blood pressure measurement was done with an automated device (OMRON MIT5 Connect) with the participants in a sitting position after at least 15min rest. Three measurements were taken on the right arm 2-3min apart and the average of the second and third readings used for data analysis. Weight (to the nearest kilogram) was measured using a weighing scale while height (to the nearest 0.5cm) was measured with a wooden stadiometer. Body mass index (BMI) in kg/m² was calculated as weight (kg)/[height(m)]².

Definitions: hypertension diagnosis was retained when a participant reported having been on BP-lowering medications over the last 15 consecutive days or an elevated BP value with systolic blood pressure (SBP) ≥140mmHg and/or diastolic blood pressure (DBP) ≥90mmHg obtained from 3 different consultations, documented in the participant’s medical records. The severity of hypertension was defined as SBP of 140-159mmHg or a DBP 90-99mmHg for stage 1 and SBP ≥160mmHg or diastolic blood pressure (DBP) ≥100mmHg for stage 2 JNC 7 [14]. The antihypertensive drug prescription considered was the most recent prescription. The control of hypertension was defined according to the Eighth Joint National Committee (JNC8) as BP <140/90mmHg in hypertensive patients <60 years old, diabetic patient or patients with renal failure and BP <150/90mmHg in hypertensive patients ≥60 years old who are not diabetic and without renal failure [12]. Monotherapy was defined as treatment containing a single active ingredient. Combination therapy was defined as treatment containing either two active ingredients.
(bitherapy), three active ingredients (tritherapy) or four active ingredients (quadritherapy). A fixed-drug combination was defined as a drug containing two or more active ingredients in a single tablet. Participants who smoked at least one cigarette per day at the time of the study were classified as current smokers, and those who had smoked for at least 3 years in the past but had stopped by the time of the study were classified as ex-smokers. Prevalent diabetes was based on ongoing antidiabetic drugs or a documented history of diabetes.

**Data analysis:** categorical variables are expressed as frequencies and percentages while quantitative variables are expressed as mean and standard deviation for normally distributed variables and median and 25th-75th percentiles for skewed variables. The chi-square and Fischer exact test were used to compare categorical variables as appropriate in the univariate analysis. Variables that were statistically significant in the univariate model were used for analysis in the multivariate analysis. Logistic regressions adjusted for age, gender and center were used to determine the significant predictors of prescription of antihypertensive medications and BP control. For the prescription of antihypertensive medications, the predictor variables were; the age, duration of hypertension, duration of practice, the severity of hypertension, average monthly income, prescriber, presence of comorbidities and the dependent variable was the different treatment regimen. When assessing factors that influence BP control, predictor variables were; age, gender, marital status, occupation, physical activity, smoking, BMI and treatment regimen while the dependent variable was the level of BP control. All statistical analyses were performed using SPSS version 23 IBM and p-value ≤0.05 was taken to indicate significance.

**Ethical consideration:** ethical clearance was obtained from the Institutional Review Board of the Faculty of Health Sciences, the University of Buea and the study conformed to the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from each eligible participant before inclusion.

**Results**

**General characteristic of the study population:** a total of 408 participants were included in the study (Figure 1). The mean age of participants was 61.1 ± 12.2 years (minimum-maximum 21-98 years); 272 (63.7%) were female, 240 (59.4%) were married, 207 (51.1%) were unemployed and 153 (38.5%) had primary education and 41 (10.3%) had no formal education (Table 1). The median diagnosed duration of hypertension was 6 years and the median duration of current treatment was 22.0 weeks. In all, 76.2% of the participants had associated comorbidity, while 352 (87.3%) were receiving treatment from a doctor (Table 2).

**Prescription patterns of antihypertensive drugs:** seventy-two percent of participants were prescribed the proprietary form of drugs, 16% prescribed the generic form and 12% were prescribed both the generic and proprietary forms. The median number of drugs received by the participants was one. The average monthly cost of antihypertensive medication was 17.7 ± 13.7 dollars. Two hundred and eighty-two (71.9%) of participants paid for their drugs from out of pocket money while only 4 (1.0%) benefitted from insurance coverage. In all, 93.1% of patients were prescribed a once-daily drug regimen. Of the 408 prescriptions, 44% were bitherapy, 31% monotherapy and 26% contained three or more drugs (Figure 2). Among the 283 participants on combination therapy, 121(42.8%) were on fixed combinations.

Calcium channel blockers (CCB) were the most prescribed antihypertensive in 35.1% of the participants either as single or combination therapy with the most frequent molecule been amlodipine (30.5%). Thiazide/thiazide-like diuretic (TD/TLD) in 26.1% was the second most prescribed therapeutic class, with the most frequently used molecule being hydrochlorothiazide (HCT,14.6%); while angiotensin-converting enzyme inhibitors...
(ACEI) in 19.5% was the third leading class, with the most frequently used molecule being perindopril (7.0%); (Figure 3). Among participants on combination therapy, ACEI+TD/TLD (19.4%), CCB+TD/TLD (18.7%) and ACEI+CCB+TD/TLD (10.6%) were the most frequently used combinations. The severity of hypertension, duration of hypertension and the presence of comorbidity were the independent determinants of prescription of antihypertensive drugs (Table 3).

Blood pressure control: in all, 211 (51.7%) participants had a controlled level of BP; with no gender difference in proportions of controlled hypertension (50% in men Vs 52.6% in women p=0.70). By treatment regimens, the proportion of controlled hypertension was 60% for monotherapy, 50.3% for bitherapy, 48.3% for tritherapy and 23.5% for quadritherapy (p=0.024). The control rate was higher in participants aged ≥60 years than in those aged <60 years (59.9% vs 40.4%, p <0.01), and varied by BMI status (p=0.046). In age, sex and center adjusted logistic regression, BMI <25 (OR 2.3;1.2-4.3), been on monotherapy (OR 5.2;1.6-17.3) and Bitherapy (3.4;1.1-11.3) were significant predictors of BP control.

Discussion

Our study revealed that, calcium channel blockers (CCB) were the most commonly prescribed antihypertensive in a third of participants, followed by thiazide/thiazide-like diuretic (TD/TLD) and angiotensin-converting enzyme inhibitor (ACEI). About two-thirds of participants were on combination therapy, with the severity of hypertension and duration of hypertension being the predictor of prescription. About half of treated patients were at target BP control level with the age of patients, BMI and treatment regimen being important correlates of BP control. The patterns of prescription in our study were similar to those found by Menanga et al. in a study in urban Cameroon in 2016 [25]. They are also in line with JNC on Prevention, Detection, Evaluation, and Treatment of high blood pressure guidelines which recommend the use CCB and Thiazide/thiazide-like diuretics as first-line drugs in the management of hypertension among blacks [12]. However, a dissimilarity was found in the prescription of antihypertensive in a study done by Adejumo et al. and Busari et al. in Nigeria who found that diuretics were the commonly prescribed antihypertensive medications [26, 27]. This difference could be due to the availability and accessibility of CCB in our setting and the fact that the majority of our patients were elderly. Although diuretics which are relatively cheaper were traditionally the mainstay of hypertension management in this age group, other classes of antihypertensives such as CCB, ACEI and sympatholytic have proven to be beneficial in this age group either in single or combination therapy with little side effects [28].

The percentage of participants on combination therapy (70%) was similar to that reported by Adedapo et al. in Nigeria (79%) [29] but higher than the 50% reported by Menanga et al. in Ethiopia (50%). A higher proportion of participants in our study had comorbidities just like participants in Adedapo et al. study (77% and 88% respectively) whereas only 28% of participants in Menanga et al. study had associated comorbidities [25]. The JNC on Prevention, Detection, Evaluation, and Treatment of high BP guidelines advise that: more than 50% of patients with hypertension will require more than one drug to control their BP [30]. Studies have shown that in the presence of comorbidities coupled with other factors such as the severity of hypertension and presence of end-organ damage, the use of multiple antihypertensive drugs is likely beneficial particularly when used at low doses to reduce the side effect that may occur with higher doses of a single drug [31]. The most common drug combination used were ACEI+TD/TLD, CCB+TD/TLD and ACEI+CCB+TD/TLD which is similar to that of Menanga et al. in Cameroon and Adejumbo et al. in Nigeria and are both in accordance with the JNC 8 guidelines [12, 25, 26]. Even though the combination of 2 or more antihypertensives at fixed-dose in a single tablet is
recommended and has a beneficial effect on improving adherence to medication: 57.2% of our participants were on free drug combination. This high value could be accounted for by the very few available fixed-dose combinations as tritherapy or quadritherapy.

In our setting, the only available fixed drug combination as tritherapy was either ACEI+CCB+TD/TLD or ARB+CCB+TD/TLD which was relatively expensive when compared to a similar combination containing separate pills. Controlling hypertension is very challenging in SSA with only 7% of people with hypertension having their BP below target values [32]. In a previous nationwide study, we also reported a lower level of hypertension control among Cameroonian hypertensive with only 24.6% having their BP at target levels [33]. The control rate of hypertension among our participants was high (52%), the reason being that a higher threshold of BP control was used in this study [13]. Given that recent JNC 8 guidelines recommend a greater threshold for control BP in patients >60 years (SBP/DBP <150/90mmHg), much of our participants were beyond this age group. Also, the higher threshold for BP controlled among diabetic patients (SBP/DBP <140/90mmHg) compared to the previous cut off SBP/DBP <130/80mmHg could also account for this high control rates. Furthermore, a greater proportion of participants in our study already had associated comorbidities/complications related to hypertension. These likely increased their adherence to regular follow up visits, taking their treatment and they could also benefit from health talks and counseling given by health personnel. These findings are much higher than those by Alba-Leonel et al. (37.4%) [34]. This could be accounted for by the different definitions of BP control used in these studies which rather defined BP control as <140/80mmHg irrespective of the patient’s age or BP <130/80mmHg in diabetic patients.

However, the control rate of participants was much similar to that of Adejumo et al. [26] in Nigeria (53.6%) who used similar BP cut off to that in our study and 50.3% of Riley et al. in Ethiopia [24]. Previous studies in both developing and developed countries have shown the BP control rate to range from 15.5%-72% [34-37]. The higher BP control rate among participants in developed countries could be explained by better medical care, better education, better awareness of patients to hypertension and treatment in these countries [38]. Up to 60% of participants on monotherapy had their BP controlled. Controlled BP can be achieved by monotherapy in patients with mild hypertension compared to those with moderate to severe hypertension which will require combination therapy. More so, the pill burden with a single drug is far less demanding and it is associated with better compliance, fewer side effects or drug interaction and lower costs. This finding was similar to that of Adejumo et al. (64%) but however much higher than that obtained by Busari et al. who (34%) [26, 27]. The smaller proportion of participants on monotherapy could account for this difference in the study done by Busari et al. Most studies have shown that patients will require 2 or more antihypertensive to achieve BP control [39-41].

**Study limitations:** blood pressure control was assessed using office BP reading which may tend to underestimate the BP control rate. Also, this study was a hospital-based study done in a secondary care setting, so may not reflect the situation in the primary health care setting. Adherence to antihypertensive medication wasn’t assessed in this study.

**Conclusion**

Contemporary antihypertensive prescription patterns in our study were dominated by CCB, diuretics and ACEI with 7 of every 10 patients receiving at least 2 drugs. Half of the patients had their BP controlled which is still below optimal but far better than previous reports. The need to intensify all efforts geared towards BP control to reduce the morbidity, mortality and cost burden associated with hypertension cannot be
overemphasized. As such, providing clinicians with simple, clear and concise local hypertension guidelines with peculiarities on first-line medications and combination pharmacotherapy is critical. Also, health policymakers need to improve the availability and affordability of required medications so as to design more effective interventions that improve hypertension control and management.

What is known about this topic
- Uncontrolled hypertension is a major health issue in sub-Saharan Africa with only 7% of hypertensive patients on treatment have their BP under control;
- Prescription of antihypertensive drugs prevents adverse complications of hypertension such as stroke, myocardial infarction and heart failure;
- Several international guidelines recommend a combination of 2 or more drugs from different classes in order to achieve optimal BP control with little or no place for monotherapy.

What this study adds
- There is the absence of local guidelines to treat hypertension in several African countries and furthermore, little was known on the prescription of pharmacotherapy and its effectiveness on BP control among hypertensive blacks leaving in SSA; in our study, CCBs were the most prescribed single antihypertensive drugs;
- Monotherapy was effective in controlling BP in over 60% of our patients with uncomplicated and non-severe hypertension. Hence there is still a place for a single-drug regimen in controlling uncomplicated hypertension; clinicians in our setting tend to prescribe more combination therapy as recommended by most contemporary guidelines, especially in the presence of comorbidities;
- Although 70% of patients were treated with a combination of 2 or more drugs, BP control of hypertension could be achieved in only 50% of our participants; this study emphasizes the need for early detection, treatment and control of hypertension using combination therapy. Providing clinicians with local guidelines to support their practice in a bit to help reduce the burden of uncontrolled hypertension.

Competing interests
The authors declare no competing interests.

Authors' contributions
AD: study concept, study design, data analysis and interpretation, writing and correction of the manuscript; FFM: study concept, design, data collection, data analysis, and writing manuscript; BDT: data analysis and correction of the manuscript; SPC: study design, interpretation of data and critical revision of the manuscript. All authors proofread and approved the final version of the manuscript.

Acknowledgments
The authors are immensely thankful to those who contributed to realizing this research especially the Clinical Research Education Networking and Consultancy (CRENC) team for their timely and undoubted support. We are also grateful to each participant and administrative head.

Tables and figures
Table 1: socio-demographic characteristics of the study population
Table 2: clinical characteristics of the study population
Table 3: multivariable logistic regressions adjusted for age, sex and center
Figure 1: shows the flow process for the recruitment of participants in the current study
Figure 2: distribution of the different drug combinations
Figure 3: distribution of different classes of anti-hypertensive drugs prescribed

References

1. Jarari N, Rao N, Peela JR, Ellafi KA, Shakila S, Said AR et al. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens. 2016 Mar 27;22: 7. PubMed| Google Scholar
2. Kannel WB. Blood Pressure as a Cardiovascular Risk Factor: Prevention and Treatment. JAMA. 1996 May 22;275(20): 1571-6. PubMed| Google Scholar
3. Mathers C. The global burden of disease: 2004 update. World Health Organization; 2008. Google Scholar
4. Bloch MJ. Worldwide prevalence of hypertension exceeds 1.3 billion. J Am Soc Hypertens. 2016 Oct 1;10(10): 753-4. PubMed| Google Scholar
5. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet Lond Engl. 2005 Jan 15;365(9455): 217-23. PubMed| Google Scholar
6. Guwatudde D, Nankya-Mutyoba J, Kalyesubula R, Laurence C, Adebamowo C, Ajayi I et al. The burden of hypertension in sub-Saharan Africa: a four-country cross sectional study. BMC Public Health. 2015 Dec 5;15: 1211. PubMed| Google Scholar
7. Kengne AP, Awah PK, Fezeu L, Mbanya JC. The burden of high blood pressure and related risk factors in urban sub-Saharan Africa: Evidences from Douala in Cameroon. Afr Health Sci. 2007 Mar;7(1): 38-44. PubMed| Google Scholar
8. Kingue S, Ngoe CN, Menanga AP, Jingi AM, Noubiap JJN, Fesuh B et al. Prevalence and Risk Factors of Hypertension in Urban Areas of Cameroon: A Nationwide Population-Based Cross-Sectional Study. J Clin Hypertens. 2015 Oct 1;17(10): 819-24. PubMed| Google Scholar
9. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists’ Collaboration, Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials, Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet Lond Engl. 2000 Dec 9;356(9246): 1955-64. Google Scholar
10. Hansson L, Zanchetti A, George Carruthers S, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial HOT Study Group. Lancet. 1998 Jun 1;351: 1755-62. Google Scholar
11. Cushman WC, Ford CE, Einhorn PT, Wright JT, Preston RA, Davis BR et al. Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens Greenwich Conn. 2008 Oct;10(10): 751-60. PubMed| Google Scholar
12. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018 Mar 6;168(5): 351-8.
13. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5): 507. PubMed| Google Scholar
14. Verdecchia P, Angeli F, Verdecchia P, Angeli F. The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The Weapons Are Ready. Rev Esp Cardiol. 2003 Jan 9;56(09): 843-7. PubMed| Google Scholar
15. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013 Jul 21;34(28): 2159-219. PubMed | Google Scholar

16. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004 Mar 13;328(7440): 634-40. PubMed | Google Scholar

17. National institute for health and care excellence. Hypertension in adults: diagnosis and management. Accessed on 5th November 2018.

18. European Primary Care Cardiovascular Society Clinical practice ASH/ISH guidelines for the management of hypertension in the community. Accessed on 5th November 2018.

19. Psaty BM, Manolio TA, Smith NL, Heckbert SR, Gottdiener JS, Burke GL et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med. 2002 Nov 11;162(20): 2325-32. PubMed | Google Scholar

20. Walley T, Duggan AK, Haycox AR, Niziol CJ. Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK. J R Soc Med. 2003 Nov;96(11): 525-31. PubMed | Google Scholar

21. UNITED COUNCILS AND CITIES OF CAMEROON. BUEA. Accessed on 10th April 2018.

22. Cameroon Data Portal. Population and Housing Census of Cameroon, 2015. Accessed on 16th April 2018.

23. Cochran WG. Sampling techniques. 3d ed. New York: Wiley; 1977. 428 p. (Wiley series in probability and mathematical statistics).

24. Riley L, Guthold R, Cowan M, Savin S, Bhatti L, Armstrong T et al. The World Health Organization STEPwise Approach to Noncommunicable Disease Risk-Factor Surveillance: Methods, Challenges, and Opportunities. Am J Public Health. 2016 Jan;106(1): 74-8. PubMed | Google Scholar

25. Menanga A, Edie S, Nkoe C, Boombhi J, Musa AJ, Mfeukeu LK et al. Factors associated with blood pressure control amongst adults with hypertension in Yaounde, Cameroon: a cross-sectional study. Cardiovasc Diagn Ther. 2016 Dec 5;6(5): 439-45. PubMed | Google Scholar

26. Adejumo O, Okawa E, Iyawo I. Prescription pattern of antihypertensive medications and blood pressure control among hypertensive outpatients at the University of Benin Teaching Hospital in Benin City, Nigeria. Malawi Med J J Med Assoc Malawi. 2017 Jun;29(2): 113-7. PubMed | Google Scholar

27. Busari OA, Oluyonbo R, Fasae AJ, Gabriel OE, Ayodele LM, Agboola SM et al. Prescribing Pattern and Utilization of Antihypertensive Drugs and Blood Pressure Control in Adult Patients with Systemic Hypertension in a Rural Tertiary Hospital in Nigeria. Am J Intern Med. 2014 Dec 26;2(6): 144. Google Scholar

28. Weber MA, Neutel JM, Cheung DG. Hypertension in the aged: A pathophysiologic basis for treatment. Am J Cardiol. 1989 May;63(16): 2560-72. PubMed | Google Scholar

29. Adedapo AD, Adedeji WA, Adeosun AM, Olaremi J, Okunlola CK. Antihypertensive drug use and blood pressure control among inpatients with hypertension in a Nigerian tertiary healthcare centre. Int J Basic Clin Pharmacol. 2016;5(3): 696-701. Google Scholar

30. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19): 2560-72. PubMed | Google Scholar
31. Odili V, Oghagbon E, Ugwa N, Ochei U, Aghomo O. Adherence to International Guidelines in the Management of Hypertension in a Tertiary Hospital in Nigeria. Trop J Pharm Res. 2008 Jun 23;7(2). Google Scholar

32. Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in sub-saharan Africa: a systematic review and meta-analysis. Hypertens Dallas Tex 1979. 2015 Feb;65(2):291-8. PubMed | Google Scholar

33. Dzudie A, Kengne AP, Muna WFT, Ba H, Menanga A, Kouam CK et al. Prevalence, awareness, treatment and control of hypertension in a self-selected Sub-Saharan African urban population: a cross-sectional study. BMJ Open. 2012 Jan 1;2(4): e001217. PubMed | Google Scholar

34. Alba-Leonel A, Carvajal A, Fierro I, Castillo-Nájera F, Campos-Ramos O, Villa-Romero A et al. Prescription patterns of antihypertensives in a community health centre in Mexico City: a drug utilization study. Fundam Clin Pharmacol. 2016 Jun;30(3):276-81. PubMed | Google Scholar

35. Sarganas G, Knopf H, Grams D, Neuhauser HK. Trends in Antihypertensive Medication Use and Blood Pressure Control Among Adults with Hypertension in Germany. Am J Hypertens. 2016 Jan;29(1):104-13. PubMed | Google Scholar

36. Goverwa TP, Masuka N, Tshimanga M, Gombe NT, Takundwa L, Bangure D et al. Uncontrolled hypertension among hypertensive patients on treatment in Lupane District, Zimbabwe, 2012. BMC Res Notes. 2014 Oct 8;7:703. PubMed | Google Scholar

37. Adebolu FA, Naidoo M. Blood pressure control amongst patients living with hypertension presenting to an urban district hospital outpatient clinic in Kwazulu-Natal. Afr J Prim Health Care Fam Med. 2014 Jul 28;6(1):E1-6. PubMed | Google Scholar

38. Mallat SG, Samra SA, Younes F, Sawaya M-T. Identifying predictors of blood pressure control in the Lebanese population: a national, multicentric survey - I-PREDICT. BMC Public Health. 2014 Nov 5;14:1142. PubMed | Google Scholar

39. Glorioso N, Thomas M, Troffa C, Argiolas G, Patel S, Baek I et al. Antihypertensive efficacy and tolerability of aliskiren/amlopidine single-pill combinations in patients with an inadequate response to aliskiren monotherapy. Curr Vasc Pharmacol. 2012 Nov;10(6):748-55. PubMed | Google Scholar

40. Pfeiffer D, Rennie N, Papst CC, Zhang J. Efficacy and tolerability of aliskiren/amlopidine single-pill combinations in patients who did not respond fully to amlopidine monotherapy. Curr Vasc Pharmacol. 2012 Nov;10(6):773-80. PubMed | Google Scholar

41. Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998 Dec;12(12):861-6. PubMed | Google Scholar
| Characteristics                          | Male (n=136)   | Female (n=272) | p-value |
|-----------------------------------------|----------------|----------------|---------|
| Mean Age (±SD), years                   | 61.1 (±11.6)   | 61.1 (±12.5)   | 0.984   |
| Age groups, n (%)                       |                |                | 0.495   |
| 20–39                                   | 7 (5.1)        | 14 (5.1)       |         |
| 40–59                                   | 45 (33.1)      | 105 (38.6)     |         |
| 60–79                                   | 80 (58.8)      | 140 (51.5)     |         |
| 80–100                                  | 4 (2.9)        | 13 (4.8)       |         |
| Marital status n (%)                    |                |                | <0.001  |
| Single                                  | 5 (3.7)        | 35 (12.9)      |         |
| Married                                 | 115 (84.6)     | 125 (46.0)     |         |
| Divorced                                | 1 (0.7)        | 6 (2.2)        |         |
| Widow(er)                               | 14 (10.3)      | 103 (37.9)     |         |
| Level of education n (%)                |                |                | <0.001  |
| No formal education                     | 6 (4.4)        | 45 (16.5)      |         |
| Primary                                 | 41 (30.1)      | 114 (41.9)     |         |
| Secondary                               | 49 (36.0)      | 64 (23.5)      |         |
| Tertiary                                | 40 (29.4)      | 49 (18.0)      |         |
| Occupation n (%)                        |                |                | <0.001  |
| Employed                                | 59 (44.0)      | 75 (27.7)      |         |
| Unemployed                              | 40 (29.9)      | 167 (61.6)     |         |
| Retired                                 | 35 (26.1)      | 27 (10.0)      |         |
| Student                                 | 0              | 2 (0.7)        |         |
Table 2: clinical characteristics of the study population

| Characteristics | Male | Female | p-value |
|-----------------|------|--------|---------|
| Median duration of hypertension (25th-75th percentiles), years | 5 (3-10) | 6.5 (3-12) | 0.397 |
| *Mean monthly income ($) | 313.6 | 214.7 | 0.071 |
| Median duration of current treatment (25th-75th percentiles), weeks | 20 (7.3-52) | 24 (8.1-54.5) | 0.266 |
| Median duration of follow-up (25th-75th percentile), months | 12 (5-24) | 12 (6-36) | 0.527 |
| Mean SBP (±SD), mmHg | 143.5 (±24.2) | 141.4 (±21.4) | 0.374 |
| Mean DBP(±SD), mmHg | 85.4 (±13.3) | 86.7 (±12.5) | 0.337 |
| Associated comorbidities /risk factors | | | |
| Smoking n (%) | 15 (11.0) | 1 (0.4) | <0.01 |
| Body Mass Index n (%) | | | 0.001 |
| Normal | 37 (32.7) | 43 (18.7) |
| Overweight | 45 (39.8) | 79 (34.3) |
| Obese | 31 (27.4) | 108 (47.0) |
| Diabetes mellitus n (%) | 85 (63.0) | 157 (57.9) | 0.387 |
| History of chronic kidney disease n (%) | 116 (85.3) | 248 (91.2) | 0.102 |
| History Heart failure n (%) | 125 (92.6) | 245 (90.4) | 0.586 |
| History Ischemic Heart disease n (%) | 125 (93.3) | 257 (95.2) | 0.575 |
| History of Stroke n (%) | 117 (86) | 245 (90.4) | 0.246 |

*conversion unit from CFA to dollars was 581

Table 3: multivariable logistic regressions adjusted for age, sex and center

| Variables | Bitherapy OR (95% CI) | Tritherapy OR (95% CI) | Quaditherapy OR (95% CI) |
|-----------|-----------------------|------------------------|--------------------------|
| Age of patient < 60 years | 1.8 (0.9-4.0) | 2.2 (0.9-5.4) | 4.1 (0.8-22) |
| Age of doctor < 39 years | 1.4 (0.8-2.4) | 1.6 (0.8-2.9) | 2.7 (0.9-8.1) |
| Duration of practice < 12 years | 0.9 (0.5-1.7) | 1.2 (0.6-2.4) | 2 (0.6-6.2) |
| Duration of hypertension < 6 years | 0.6 (0.5-1.2) | **0.4 (0.2-0.7)** | 0.4 (0.1-1.1) |
| Severity of hypertension | | | |
| Normal | 0.9 (0.4-1.9) | 1.8 (0.6-5.1) | 1.5 (0.3-9.2) |
| Mild | 1.4 (0.9-2.4) | **4.5 (2.2-9.2)** | 2.2 (0.7-7.4) |
| Prescribing doctor | | | |
| General practitioner | 0.8 (0.4-1.4) | 0.5 (0.2-1.1) | 0 |
| Patient’s monthly income < 173$ | 1.1 (0.4-2.7) | 0.2 (0.6-5.8) | 0.6 (0.1-3.4) |
| History of diabetes | 1.3 (0.8-2.1) | **1.8 (1.1-3.4)** | 1.1 (0.4-3.1) |
| History of stroke | 1.1 (0.5-2.4) | 0.6 (0.3-1.5) | 1.8 (0.2-15) |
| History of chronic kidney disease | 0.5 (0.2-1.2) | 0.7 (0.3-2.1) | 0.3 (0.1-1.4) |
| History of heart failure | 1.3 (0.5-3.4) | 0.5 (0.2-1.3) | **0.2 (0.0-0.5)** |
| History of ischaemic Heart Disease | 0.3 (0.1-1.5) | 0.3 (0.05-1.5) | **0.02 (0.0-0.1)** |

Reference is monotherapy
Figure 1: shows the flow process for the recruitment of participants in the current study.

Figure 2: distribution of the different drug combinations.
Figure 3: distribution of different classes of anti-hypertensive drugs prescribed